BAARERSTRASSE 14, ZUG, V8
Shareholders Approve CRISPR Therapeutics AG 2026 Stock Option Plan
Provides Business Update and Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Prices Upsized Convertible Senior Notes Offering
Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Other Events
Provides Business Update and Reports Third Quarter 2025 Financial Results
CRISPR Therapeutics Files Prospectus Supplement for $600 Million Offering
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence